This is a working overview of regulatory status, written for readers who want more than a one-paragraph summary but less than a textbook.
Reviewed 2025-11-27. Anything still debated is marked as such rather than presented as settled.
AOD-9604 is a synthetic peptide whose sequence matches the C-terminal fragment of human growth hormone, specifically residues 176 through 191. This region differs from the full hormone in its receptor interactions. The peptide is not a growth hormone secretagogue and does not bind the growth hormone receptor in the same manner. Researchers have examined it for effects on lipid metabolism, but its exact pharmacological profile remains an active area of study.
Development of AOD-9604 began in the 1990s as scientists sought to isolate metabolic effects of growth hormone without its growth-promoting actions. Early laboratory work focused on fat cells and animal models. Several human trials followed, examining changes in body composition and fat mass. Results have been mixed, and the peptide has not progressed to widespread clinical approval. Interest continues in research settings, particularly regarding its mechanism and potential metabolic targets.
AOD-9604 is typically supplied as a lyophilized white to off-white powder. In this form, it is relatively stable when kept cool, dry, and protected from light. Common storage recommendations place it at −20 °C or below for long-term retention. Reconstituted solutions are less stable and are often kept at 2–8 °C for short periods. Freeze-thaw cycles should be minimized because they can promote aggregation or loss of peptide content. Vials are usually sealed under inert gas to reduce oxidation.
Identity and purity are commonly checked with reversed-phase high-performance liquid chromatography and mass spectrometry. RP-HPLC separates the peptide from related impurities and can estimate purity by peak area. Mass spectrometry confirms molecular mass and helps detect sequence variants or truncations. Some laboratories use amino acid analysis or peptide mapping for additional characterization. No single method proves biological activity; these techniques establish chemical identity and purity only. They also require suitable reference standards for confident comparison.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Peptide fragment | Corresponds to hGH residues 176-191 |
| Common synonyms | AOD9604, hGH 176-191 | Also written as AOD-9604 |
| Typical form | Lyophilized powder | Often supplied in sealed vials |
| Solubility | Water-soluble | Dissolves in aqueous buffers |
| Regulatory status | Not approved as drug | Banned in sport; varies by country |
Detection and characterization of AOD-9604 in research and anti-doping settings typically rely on mass spectrometry coupled with liquid chromatography. These methods can identify the peptide by its mass and fragmentation pattern. Immunoassays may also be used in some screening contexts, but they can cross-react with related peptides. Because the molecule is small and may be present at low concentrations, sample preparation and method validation are important. Confirmatory analysis usually requires comparison with a certified reference standard.
In laboratory settings, AOD-9604 is commonly supplied as a lyophilized powder and stored cold to limit degradation. Reconstituted solutions are typically kept refrigerated or frozen, depending on the buffer and concentration, and protected from repeated freeze-thaw cycles. Stability can be influenced by pH, temperature, and the presence of proteases. Purity is usually assessed by high-performance liquid chromatography and mass spectrometry. These practices support reproducibility, but they do not imply safety or efficacy for any human use.
Research interest in AOD-9604 often focuses on whether it can influence lipid metabolism without the growth-promoting or glucose-related effects of full-length hGH. This question remains unresolved, and findings depend on model, dose, and measurement method. Some reviews treat the peptide as a historical obesity candidate rather than an active therapeutic. Others cite it in discussions of peptide fragments, metabolic signaling, and performance-enhancing substances. Clear conclusions are limited by the small number of rigorous, independent human studies.
AOD-9604 has been investigated primarily as a potential treatment for obesity and related metabolic conditions. Early laboratory work examined its effects on fat cells, and later studies moved into animal models and human clinical trials. Some trials reportedly reached Phase II, but the program did not lead to an approved medicine. Published summaries often note that weight-loss results were modest or inconsistent. The full trial data are not all publicly available in detail.
Regulatory treatment of AOD-9604 has varied. In sports anti-doping, the peptide became widely discussed during a 2013 investigation into an Australian professional sports club. Authorities at the time debated whether it fell under prohibitions on growth hormone and related substances. Later clarifications and updated lists have addressed the compound in different ways. Anyone seeking current status should consult the latest applicable rules, and commercial supply for human use is not authorized in major markets.
Harbury and Halpin developed DNA template libraries that direct like genes the synthesis of DNA encoded organic libraries. The members of the template combinatorial library contain the codes of all BBs and their order of couplings. The figure shows one member of a simple ssDNA template library (A) containing the codes of three BBs (2, 4, 6) that planned to be successively attached. The coding regions are separated by the same non-coding regions (1, 3, 5, 7) in all members. The sequence directed procedure uses a series of columns of resin beads each coated with the anticodon of one of the BBs (B). When the template library is transferred to an anticodon column the proper template member is captured by hybridization then is coupled with the appropriate BB. After finished with all anticodon columns of a coupling position (CP) the libraries are eluted from the beads of the anticodon columns mixed and the mentioned operations are repeated with the series of anticodon columns of the next CP. In figure, C shows one member of the template library captured by the “yellow” second CP anticodon library. The template contains the “red” BB already coupled in CP1 and the “yellow” BB attached after its capture. The final library contains all of the synthesized organic compounds attached to their encoding DNA oligomers.
Papaver somniferum, commonly known as the opium poppy or breadseed poppy, is a species of flowering plant in the family Papaveraceae. It is the species of plant from which both opium and poppy seeds are derived and is also a valuable ornamental plant grown in gardens. Its native range is the western Mediterranean region, but has since been obscured by widespread introduction and cultivation since ancient times to the present day. It is now naturalised across much of the world with temperate climates.
=== Binding mechanism === The receptor for advanced glycation end products (RAGE) is a multiligand member of the immunoglobulin superfamily, originally identified due to its ability to bind advanced glycation end products (AGEs). AGEs accumulate in various chronic conditions such as diabetes and renal failure. However, RAGE also binds other ligands, notably proteins of the S100/calgranulin family, such as EN-RAGE and S100B, which play significant roles in inflammatory processes. RAGE ligands interact with the receptor through its extracellular domain, triggering a cascade of intracellular signaling pathways. These pathways lead to the activation of key transcription factors like nuclear factor kappa B (NF-κB), which is central to the expression of proinflammatory cytokines, adhesion molecules (such as VCAM-1 and ICAM-1), and other mediators of inflammation. Upon binding ligands like EN-RAGE or S100B, RAGE stimulates various inflammatory responses, including endothelial cell activation, mononuclear cell migration, and the production of cytokines such as TNF-α and IL-1β. These interactions between RAGE and its ligands contribute to chronic inflammatory conditions, including atherosclerosis, Alzheimer's disease, and diabetic complications. Inhibiting the RAGE-ligand interaction—through the use of soluble RAGE (sRAGE) or specific antibodies—can suppress these inflammatory responses, offering potential therapeutic strategies.
Sources: en.wikipedia.org
=== Books === ——; Wilson, E. B. (1985) [Originally published in 1935]. Introduction to Quantum Mechanics with Applications to Chemistry. Reprinted by Dover Publications. ISBN 978-0-486-64871-2. —— (1939). The Nature of the Chemical Bond and the Structure of Molecules and Crystals. Cornell University Press. —— (1947). General Chemistry: An Introduction to Descriptive Chemistry and Modern Chemical Theory. Freeman. Greatly revised and expanded in 1947, 1953, and 1970. Reprinted by Dover Publications in 1988. —— (1950). College Chemistry: An Introductory Textbook of General Chemistry. Freeman. 2nd edition, 1955. 3rd edition, 1964. —— (1970) [Originally published in 1964]. The Architecture of Molecules. (Illustrated by Roger Hayward). San Francisco: W. H. Freeman and Company. ISBN 978-0-7167-0158-3. Manuscript notes and typescripts (clear images) —— (1958). No more war!. Dodd, Mead & Co. ISBN 978-1-124-11966-3 —— (1977). Vitamin C, the Common Cold and the Flu. Freeman. ISBN 978-0-7167-0360-0. —— (1987). How to Live Longer and Feel Better. Avon. ISBN 978-0-380-70289-3. Cameron, E.; —— (1993). Cancer and Vitamin C: A Discussion of the Nature, Causes, Prevention, and Treatment of Cancer With Special Reference to the Value of Vitamin C. Camino. ISBN 978-0-940159-21-1. —— (1998). Linus Pauling On Peace: A Scientist Speaks Out on Humanism and World Survival. Rising Star Press. ISBN 978-0-933670-03-7. Hoffer, Abram; —— (2004). Healing Cancer: Complementary Vitamin & Drug Treatments. Toronto: CCNM Press. ISBN 978-1-897025-11-6. Ikeda, Daisaku; —— (2008).
The average lifespan in the wild is 18 years, and it is quite possible for wild individuals to survive for more than 23 years. The record age of a wild individual was 39 years, while that in captivity was 44 years. The average annual survival rate is variable, ranging from 86% in Florida to 73% in Virginia and North Carolina. In Minnesota, 99% of wintering adult bears were able to survive the hibernation cycle in one study. A study of American black bears in Nevada found that the amount of annual mortality of a population of bears in wilderness areas was 0%, whereas in developed areas in the state this figure rose to 83%. Survival in subadults is generally less assured. In Alaska 14–17% of subadult males and 30–48% of subadult females were found in a study to survive to adulthood. Across the range, the estimated number of cubs who survive past their first year is 60%. With the exception of the rare confrontation with an adult brown bear or a gray wolf pack, adult black bears are not usually subject to natural predation. Scats with fur inside of them and a carcass of an adult sow with puncture marks in the skull indicate black bears may occasionally be killed by jaguars in the southern parts of their range. In such scenarios, the big cat would have the advantage if it ambushed the bear, killing it with a crushing bite to the back of the skull. Cubs tend to be more vulnerable to predation than adults, with known predators including bobcats, coyotes, cougars, gray wolves, brown bears and other bears of their own species.
Research into the clinical use of a recombinant form of human Activated Protein C (rhAPC) known as Drotrecogin alfa-activated, branded Xigris by Eli Lilly and Company, has been surrounded by controversy. Eli Lilly ran an aggressive marketing campaign to promote its use for people with severe sepsis and septic shock and sponsored the 2004 Surviving Sepsis Campaign Guidelines. However, a 2012 Cochrane review found that its use cannot be recommended since it does not improve survival and increases bleeding risk. In October 2011, Xigris was withdrawn from the market by Eli Lilly due to a higher mortality in a trial among adults.
== Function == The protein encoded by this gene is a serum protein that binds insulin-like growth factors, increasing their half-life and their vascular localization. Production of the encoded protein, which contains twenty leucine-rich repeats, is stimulated by growth hormone. Three transcript variants encoding two different isoforms have been found for this gene.
Sources: en.wikipedia.org
AOD-9604 is a synthetic peptide fragment of human growth hormone, corresponding to amino acids 176-191. It is studied for potential effects on fat metabolism, but it is not approved as a drug in most countries. Its exact mechanism remains under investigation.
No, it is a small fragment of the full growth hormone protein. It does not appear to stimulate growth or increase growth hormone levels in the same way. Its actions are thought to be more limited to metabolic pathways.
Regulatory status varies. It is not approved for medical use in the United States or many other countries. It is banned in sport by WADA, and its sale as a supplement or research chemical may be subject to legal restrictions.
Lyophilized powder is commonly stored at −20 °C or below, protected from light and moisture. Reconstituted solutions are typically kept refrigerated and used within a limited period.